ADVERTISEMENT
Ajanta Pharma Q4 Review: Revenue Inline But Margins Contract- Systematix Maintains 'Buy', Cuts Target Price
Systematix retains Buy with a revised target price of Rs 3,293 based on 35x FY27E earnings per share.
02 May 2025, 11:03 AM IST 
Save
Ajanta Pharma Ltd.’s Q4 FY25 revenue (Rs 11,704 million) was in-line with expectations (up 11% YoY and 2% QoQ), but Ebitda came in lower owing to higher than expected employee costs during the quarter.
(Photo: Volodymyr Hryshchenko/ Unsplash.
Ajanta Pharma reported Q4 FY25 revenue of Rs 11.7 billion, up 11% YoY and 2.1% QoQ. Ebitda stood at Rs 2.97 billion, up 6.8% YoY but down 7.4% QoQ. Ebitda margin stood at 25.4%, down 102 bps YoY and 260 bps QoQ. PAT stood at Rs 2.3 billion, up 11.1% YoY but down 3.3% QoQ. PAT margin stood at 19.2%, flat YoY and down 107 bps QoQ.
